Effective prevention vs the online influencers
18 Sep, 2026
What does medical progress actually mean? This week's Geneva Association Health and Demography Conference in London grappled with that question. The "wellness industrial complex" sells new digital monitoring devices and testing direct to the consumer. Meanwhile the basics of prevention are often right in front of us but underused and valued. OECD data shows health systems spend just 3% of their budgets on prevention. ILC's David Sinclair reflects on why making (evidence based) prevention pay has never been more urgent.
This week, the Geneva Association's Health and Demography Conference in London explored what medical progress means.
It sounds as though there should be an obvious answer. A new drug is approved. A cancer is caught earlier. A test becomes available. Progress?
The opening keynote was delivered by Deborah Cohen, senior visiting fellow at LSE Health and the author of Bad Influence: How the Internet Hijacked Our Health. Deborah painted a vivid picture of what she called the "wellness industrial complex" – a sprawling parallel healthcare system of influencers, direct-to-consumer tests, private hormone clinics, continuous glucose monitors and AI chatbots, all growing faster than the evidence base that underpins them. We have, she argued, acquired a new set of gatekeepers - platforms, algorithms, commercial companies - who are increasingly mediating the health information we receive. Unlike doctors, they carry no duty of care.
It reminded me of arguments that Dr Margaret McCartney has been making for many years (including at our Future of Ageing Conference). In her book The Patient Paradox, Dr McCartney described a world in which we overtreat the well and undertreat the sick – a trap driven by what she called "sexed-up medicine," in which too much testing of healthy people wastes resource, worsens health inequalities, and drains the professional time needed for those who are genuinely ill.
Deborah Cohen made precisely this argument, updated for the social media age. The multi-cancer early detection test developed by Grail is a telling example. The NHS-Galleri trial - involving nearly 143,000 participants - missed its primary endpoint when results were published earlier this year, failing to achieve a statistically significant reduction in late-stage cancer diagnoses across three rounds of screening.
The blood test designed to screen for more than 50 types of cancer before symptoms appear is still available and sold privately. The point made was that tests, like drugs, carry harms as well as benefits – anxiety, follow-up investigations, unnecessary biopsies, and cost. So we really need to be sure they work.
The distinction between innovation and progress became the organising thread of the panel that followed.
According to OECD Health at a Glance 2025, countries spend on average just 3% of their health budgets on prevention. It briefly doubled during the Covid-19 pandemic - when the case for investing upstream became impossible to ignore - then fell straight back. And yet the conditions that most determine how well we age - cardiovascular disease, type 2 diabetes, hypertension, metabolic ill-health - are, to a significant degree, preventable or at least deferrable.
The panel returned to the same structural trap. Insurance cycles of two to three years, political cycles of four or five, quarterly reporting - none of these are compatible with the timescale on which prevention works.
John Schoonbee, global chief medical officer at Swiss Re, spoke compellingly about metabolic health - and about how the basics get overlooked. The panel noted that even hypertension, where effective treatment has been available for decades and the drugs are virtually free, remains poorly controlled in large parts of the world. The gap between knowing what works and delivering it at scale is enormous, and it falls hardest on those with the least resource to navigate the system alone.
That is the inequality the wellness industrial complex tends to obscure. The people most likely to buy a continuous glucose monitor they do not need, or to pursue a multi-cancer screening test of uncertain benefit, are not typically those with the worst health outcomes.
The real prevention dividend - the one that would genuinely transform healthy life expectancy as we age - lies in addressing the fundamentals: blood pressure, physical activity, nutrition, and the social determinants that still predict outcomes. Adherence to existing effective medicines and uptake of vaccines should be on this list. But these things are not glamorous as the new digital monitoring device or blood test.
Innovation is not the enemy here. But innovation without access, adoption, or the systems capable of delivering value at scale is not progress. And progress measured only in new treatments, while neglecting the upstream investments that prevent disease in the first place, is not a health strategy. It is an expensive way of managing failure.
At ILC, making prevention pay is one of our most urgent priorities. If this week’s conference told us anything, it is that the will to change is present in the room – from clinicians, from insurers, from health economists. What is still missing is the structural courage to reorder the incentives
At Future of Ageing in March 2027 we will have a strand of events designed around the theme of Making Prevention Pay.
David Sinclair
Chief Executive
David has worked in policy and research on ageing and demographic change for over 20 years. He is a recognised expert on longevity, with particular interests in older consumers, active ageing, financial services, adult vaccination and the role of technology in an ageing society. He has deep knowledge of UK and global ageing issues, spanning health and care, pensions, housing, transport and consumption. David regularly presents internationally on longevity and demographic change and has published widely on topics including transport, technology, health and consumer markets. David is an international advisor to the Sau Po Centre on Ageing at the University of Hong Kong and a member of the external advisory board for the University of Surrey Centre of Excellence on Ageing. He has worked with the pan-European AGE Platform for 15 years and is a former vice-chair of the government’s Consumer Expert Group for Digital Switchover. Prior to joining the ILC, David was head of policy at Help the Aged, leading a team of policy advisers, and has held senior policy and public affairs roles across the voluntary sector.

